For patients with intermediate-high-risk acute pulmonary embolism, catheter-directed thrombolysis with alteplase combined with anticoagulation therapy resulted in a significantly lower overall mortality and other adverse outcomes compared to anticoagulation therapy alone, as revealed by an open-label randomized trial.
Study Details
Among 558 patients, only 0.7% in the thrombolysis group experienced a composite endpoint comprising death from any cause, pulmonary embolism recurrence, or cardiorespiratory failure within 7 days, whereas 6.8% of those receiving standard anticoagulation treatment experienced these outcomes (relative risk [RR] 0.10, 95% CI 0.02-0.44, P<0.001), reported Dr. Viktor Kocka from Charles University in Prague at the European Society of Cardiology Congress in Munich.
The observed difference was primarily attributed to a lower incidence of cardiorespiratory decompensation or collapse in the thrombolysis group (0.7% versus 5.4%; RR 0.13, 95% CI 0.03-0.57).
Mortality Rates
No deaths occurred in the thrombolysis group within seven days, while four deaths were noted in the standard care group. By the 30-day mark, there was one death in the thrombolysis group compared to no deaths in the standard care group. Pulmonary embolism recurrence was reported in one patient on anticoagulation and in two patients on thrombolysis who faced cardiorespiratory decompensation or collapse.
Implications for Treatment
Standard practice for intermediate-high-risk acute pulmonary embolism often revolves around anticoagulation, with rescue reperfusion therapies being employed for severe deterioration. The researchers argue that this trial supports the idea that, for select patients in interventional centers, early catheter-based reperfusion may preempt serious deterioration and promote a quicker recovery.
In-hospital mortality rates for pulmonary embolism are comparable to or exceed those for myocardial infarctions, ranging from 10% to 20%. Dr. Kocka highlighted a significant clinical gap, as most patients still receive treatment similar to what was common thirty years ago, primarily involving routine anticoagulation.
“I hope our findings, along with previously published data, will influence future European guidelines and fundamentally transform our treatment approach to pulmonary embolism,” he remarked. The study findings indicate that 17 patients would need to be treated to prevent one adverse outcome.
Expert Opinions
Dr. Inderjit Singh from Yale School of Medicine expressed that while the lack of recurrence impact was predictable, it was significant to note that the primary outcome was mainly due to the reduction in cardiorespiratory issues rather than a mortality benefit. He emphasized the importance of preventing hemodynamic deterioration in this patient group.
However, he raised concerns about the risks associated with the thrombolysis procedure, noting cases of intracranial hemorrhage within the thrombolysis group and the absence of long-term outcome data, while remaining cautiously optimistic about safety. He also highlighted that the study was conducted in highly specialized centers raising concerns about its applicability in smaller facilities.
If these findings are validated and incorporated into future guidelines, a shift towards more proactive management strategies may occur for patients categorized as intermediate-risk in pulmonary embolism treatment.
Conclusion
The trial recruited 558 individuals with intermediate-high-risk acute pulmonary embolism across 11 tertiary cardiovascular centers in the Czech Republic from October 2022 to March 2026. The diagnosis was based on imaging and laboratory assessments, revealing hemodynamic instability, a simplified Pulmonary Embolism Severity Index score of at least 1, and indicators of right ventricular dysfunction alongside elevated cardiac troponin or natriuretic peptide levels.
The median age of participants was 64; 40.9% were women, and nearly all (98.2%) presented with bilateral pulmonary embolism. Catheter-directed thrombolysis was initiated within a median of 76 minutes post-randomization, with a majority (89.3%) receiving treatment within three hours. The alteplase administration along with heparin management reflects the trial’s structured approach.
Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider regarding medical decisions.
Fuente: https://www.medpagetoday.com/meetingcoverage/esc/122826
Join the doctors who get the most relevant medical news, curated by specialty, every week — no spam, unsubscribe anytime.
